Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 4/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176496 | 1.00 | CCR2 (0.47) | CCR2CCR5BTKPAK1TNK2 | |
| SCHEMBL24176138 | 0.93 | CCR2 (0.46) | CCR2CCR5BTKPAK1TNK2 | |
| SCHEMBL24176498 | 0.93 | CCR2 (0.46) | CCR2CCR5BTKPAK1TNK2 | |
| SCHEMBL20039984 | 0.92 | CCR2 (0.46) | CCR2CCR5BTKPAK1TNK2 | |
| SCHEMBL24176345 | 0.91 | CCR2 (0.58) | CCR2CCR5PAK1RPS6KB1 | |
| SCHEMBL3110116 | 0.90 | CCR2 (0.44) | CCR2CCR5BTKPAK1TNK2 | |
| SCHEMBL15966231 | 0.90 | CCR2 (0.44) | CCR2CCR5BTKPAK1TNK2 | |
| SCHEMBL21422799 | 0.90 | CCR2 (0.48) | CCR2CCR5 | |
| SCHEMBL24176080 | 0.90 | CCR2 (0.48) | CCR2CCR5 | |
| SCHEMBL24176087 | 0.89 | CCR2 (0.48) | CCR2CCR5BTKTNK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220133723-A1 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-20210322412-A1 | METHODS AND COMPOSITIONS FOR TREATING A CORONAVIRUS INFECTION | CENTREXION THERAPEUTICS CORP (US) | 2021-10-21 | — | — | US | disclosed |
| US-11147814-B2 | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200276197-A1 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-09-03 | — | — | US | disclosed |
| US-10568885-B2 | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-y1)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-citrate | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-20190262339-A1 | (4-((3R,4R)-3-Methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-08-29 | — | — | US | disclosed |
| US-20180207157-A1 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885BTK 3535/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885BTK 3535/4885 |
| US-10568885-B2 | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-y1)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-citrate | CS, PC, ACLY | CCR2 1449/4885CCR5 832/4885BTK 2196/4885 |
| US-20190262339-A1 | (4-((3R,4R)-3-Methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate | CS, PC, SDHA | CCR2 2393/4885CCR5 1017/4885BTK 2423/4885 |
| US-11147814-B2 | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate | CS, PC, SDHA | CCR2 2393/4885CCR5 1017/4885BTK 2423/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885BTK 3535/4885 |
| US-20210322412-A1 | METHODS AND COMPOSITIONS FOR TREATING A CORONAVIRUS INFECTION | ACE, ACE2, SARS1 | CCR2 287/4885CCR5 36/4885BTK 2363/4885 |
| US-20200276197-A1 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | CS, PC, SDHA | CCR2 2393/4885CCR5 1017/4885BTK 2423/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885BTK 3535/4885 |
| US-20180207157-A1 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | CS, PC, CPS1 | CCR2 2429/4885CCR5 1163/4885BTK 2493/4885 |
| US-20220133723-A1 | (4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE CITRATE | CS, PC, SDHA | CCR2 2393/4885CCR5 1017/4885BTK 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.